July 24th 2024
A deep dive into why this therapy has demonstrated effectiveness in various areas, including for tumors.
July 17th 2024
How teamwork among safety-net healthcare providers and pharma can make the difference.
June 7th 2024
Causal mediation analysis sought to determine how public hesitancy plays a role in the government procurement of certain vaccines.
May 30th 2024
These advancements continue to act as a key driver in helping to boost the security, efficiency, and innovation of global industries, include pharma.
May 6th 2024
Radio frequency identification (RFID) not only helps hospitals boost their medication safety standards, it also allows clinicians to continue to provide quality patient care.
Bill Gates: 'Vaccines Are A Miracle'
Coming Together
More and more parts of the healthcare industry are connecting
Specialty Pharmacy Providers Deserve Their Own Class of Trade
The emergence of specialty pharmacies, with fundamental differences from other types of pharmacy providers, warrants the establishment of manufacturer relationships
Transparency Is the Solution to the Medical-Journal 'Ghostwriting' Controversy
Drug companies should keep a goal of effective communications as the priority in medical publications
Can Fair Balance Exist on the Web?
FDA struggles with the new world of social media
The Pharma Industry's Place in a Connected Health World
New technologies are creating a powerful link between patients and healthcare providers. This Connected Health World has implications for pharmaceutical business practices
The Evolving Retail Pharmacy Channel: Implications for Manufacturers
Aggressive cost competition and the continuing growth of generic substitution will separate retailers’ interests from manufacturers’
Comparative Effectiveness With the Gloves Off
The desire to compare drugs’ efficacy is shifting from a purely medical decision to a financial one
The Rise of 'Companion' Diagnostics for Specialty Pharmaceuticals
Under the theme of personalized medicine, in vitro diagnostics will play an increasingly important role in new drug entries and new therapies
Biopharma Sales and Marketing Process Changes Are Failing to Keep up With Industry Evolution
Better internal collaboration within companies is critical to improving the vital physician-rep relationship
Our Readiness for the Attack of the Flu Bug
Getting Ready for Comparative Effectiveness Research
The most basic impulse behind CER is the desire to control healthcare costs. The implications for the biopharma industry could be significant
Information Security in Healthcare and Life Sciences Is Facing a Tipping Point
Are you prepared?
Revisiting 'To Err Is Human'
Preventable medical and medication errors should figure more prominently in the current debate on healthcare reform
Rx-360, a Global Anti-Counterfeiting Consortium, Gains Momentum
Coverage -- Access: Pharma Must Play Activist Role in Health Reform Efforts
Private and public sectors can collaborate to achieve meaningful reform
Psychoactive Drugs: Getting the Whole Support Team on Board
More so than other classes of drugs, making choices about drugs for mental health conditions require everyone around the patient to be well informed
Drug Wholesalers and the Generic Price War
Reshaping Biotechnology's Financing Relay Race
The current economic downturn may fuel the creation of new, more sustainable business models
Comparative Effectiveness: Tools, Not Rules
Newly Formed Standards Charter Organization (SCO) Lays Foundation for National HIT Agenda
The stakes are high in the debate over follow-on biologics
Could proposed legislation undercut the promise of targeted therapies?
In Defense of Sales Reps
Claims of the death of the pharma sales rep occupation have been greatly exaggerated
Here We Go Again on 'Re-Importation'
Bipartisan group of senators sponsor a revived drug-importation bill
Pharma 2020: Marketing the Future
A New Business Model for Pharma Innovation
The studio model: how film industry practices can boost pharmaceutical creativity
No surprise here: FDA drug oversight is now a 'high risk' government operation
FDA’s management of drug and device safety enters GAO’s biennial watch list
Leading in Challenging Times
It has been said that one should never miss an opportunity to make the most of a crisis. The steady stream of headlines announcing staff cuts, delays in drug approvals and a narrowing of R&D focus for pharmaceutical and biotech companies indicate there will be no shortage of opportunities in 2009.
Specialty Pharmaceuticals and the Emergence of Sub-Specialty Pharmacy
‘Ultra-orphan’ diseases will alter the specialty distribution process